HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016.

Abstract
Background Nursing home residents with atrial fibrillation are at high risk for ischemic stroke and bleeding events. The most recent national estimate (2004) indicated less than one third of this high-risk population was anticoagulated. Whether direct-acting oral anticoagulant ( DOAC ) use has disseminated into nursing homes and increased anticoagulant use is unknown. Methods and Results A repeated cross-sectional design was used to estimate the point prevalence of oral anticoagulant use on July 1 and December 31 of calendar years 2011 to 2016 among Medicare fee-for-service beneficiaries with atrial fibrillation residing in long-stay nursing homes. Nursing home residence was determined using Minimum Data Set 3.0 records. Medicare Part D claims for apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin were identified and point prevalence was estimated by determining if the supply from the most recent dispensing covered each point prevalence date. A Cochran-Armitage test was performed for linear trend in prevalence. On December 31, 2011, 42.3% of 33 959 residents (median age: 85; Q1 79, Q3 90) were treated with an oral anticoagulant, of whom 8.6% used DOAC s. The proportion receiving treatment increased to 47.8% of 37 787 residents as of December 31, 2016 ( P<0.01); 48.2% of 18 054 treated residents received DOAC s. Demographic and clinical characteristics of residents using DOAC s and warfarin were similar in 2016. Half of the 8734 DOAC users received standard dosages and most were treated with apixaban (54.4%) or rivaroxaban (35.8%) in 2016. Conclusions Increases in anticoagulant use among US nursing home residents with atrial fibrillation coincided with declining warfarin use and increasing DOAC use.
AuthorsMatthew Alcusky, David D McManus, Anne L Hume, Marc Fisher, Jennifer Tjia, Kate L Lapane
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 8 Issue 9 Pg. e012023 (05 07 2019) ISSN: 2047-9980 [Electronic] England
PMID31046504 (Publication Type: Comparative Study, Journal Article, Observational Study, Research Support, N.I.H., Extramural)
Chemical References
  • Anticoagulants
  • Factor Xa Inhibitors
  • Warfarin
Topics
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anticoagulants (administration & dosage, adverse effects)
  • Atrial Fibrillation (diagnosis, drug therapy, epidemiology)
  • Brain Ischemia (diagnosis, epidemiology, prevention & control)
  • Cross-Sectional Studies
  • Drug Substitution (trends)
  • Drug Utilization (trends)
  • Factor Xa Inhibitors (administration & dosage, adverse effects)
  • Female
  • Health Care Surveys
  • Hemorrhage (chemically induced, epidemiology)
  • Homes for the Aged (trends)
  • Humans
  • Male
  • Medicare (trends)
  • Nursing Homes (trends)
  • Practice Patterns, Physicians' (trends)
  • Risk Factors
  • Stroke (diagnosis, epidemiology, prevention & control)
  • Time Factors
  • Treatment Outcome
  • United States (epidemiology)
  • Warfarin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: